Haemonetics Corporation (NYSE:HAE) Receives Consensus Rating of “Moderate Buy” from Analysts

Shares of Haemonetics Corporation (NYSE:HAE) have received a consensus recommendation of “Moderate Buy” from the eleven ratings firms that are presently covering the firm, Marketbeat reports. Four analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $78.8889.

A number of research analysts have recently commented on the company. Citigroup reaffirmed a “neutral” rating on shares of Haemonetics in a research report on Wednesday, July 8th. Barrington Research decreased their price objective on Haemonetics from $94.00 to $89.00 and set an “outperform” rating for the company in a report on Tuesday, May 12th. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $72.00 to $80.00 in a research note on Friday, May 22nd. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Finally, Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Thursday, June 25th.

Institutional Trading of Haemonetics

Institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Haemonetics by 3.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 29,541 shares of the medical instruments supplier’s stock valued at $1,877,000 after purchasing an additional 971 shares in the last quarter. Caxton Associates LLP purchased a new position in Haemonetics during the 1st quarter valued at about $216,000. United Services Automobile Association bought a new stake in shares of Haemonetics during the first quarter valued at about $212,000. Empowered Funds LLC increased its position in shares of Haemonetics by 9.1% during the first quarter. Empowered Funds LLC now owns 4,458 shares of the medical instruments supplier’s stock valued at $283,000 after buying an additional 372 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Haemonetics by 6.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 156,138 shares of the medical instruments supplier’s stock worth $9,923,000 after buying an additional 9,051 shares in the last quarter. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Haemonetics Trading Up 1.5%

Shares of HAE stock opened at $78.56 on Friday. The company has a quick ratio of 1.87, a current ratio of 2.95 and a debt-to-equity ratio of 1.53. The firm has a market cap of $3.57 billion, a P/E ratio of 38.89, a PEG ratio of 1.59 and a beta of 0.52. The company has a 50 day moving average of $72.75 and a 200-day moving average of $66.17. Haemonetics has a 12-month low of $47.31 and a 12-month high of $87.32.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 EPS for the quarter, beating the consensus estimate of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The business had revenue of $346.35 million for the quarter, compared to the consensus estimate of $336.83 million. During the same quarter in the prior year, the business earned $1.24 earnings per share. Haemonetics’s revenue for the quarter was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Sell-side analysts anticipate that Haemonetics will post 5.21 earnings per share for the current year.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.